Drug intelligence / Profile preview

Meplex-M

Development stage: Unknown
Lead developer: Merlin Pharmaceuticals
Modality: Small Molecules
Administration: Intramuscular, Intravenous

Overview

Meplex-M is a vitamin B complex injection manufactured by Merlin Pharmaceuticals, an Indian pharmaceutical company. It is formulated as an injectable solution containing a combination of essential B vitamins, including thiamine hydrochloride (B1), riboflavine sodium phosphate (B2), pyridoxine hydrochloride (B6), niacinamide, and d-panthenol. The product is indicated for the treatment or prevention of vitamin B deficiencies resulting from inadequate dietary intake, specific illnesses, alcoholism, or increased physiological requirements during pregnancy. As a marketed generic pharmaceutical product, it provides necessary cofactors for various metabolic processes, supporting nerve health, energy production, and red blood cell synthesis.

Brand names: Meplex-M

Beyond the preview

Go deeper on Meplex-M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meplex-M.

Explore the full profile